Upregulating β-hexosaminidase activity in rodents prevents α-synuclein lipid associations and protects dopaminergic neurons from α-synuclein-mediated neurotoxicity.
Lipid binding
Neuroprotection
Parkinson’s disease
Sandhoff disease
α-Synuclein
β-Hexosaminidase
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
06 08 2020
06 08 2020
Historique:
received:
31
05
2020
accepted:
27
07
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
1
6
2021
Statut:
epublish
Résumé
Sandhoff disease (SD) is a lysosomal storage disease, caused by loss of β-hexosaminidase (HEX) activity resulting in the accumulation of ganglioside GM2. There are shared features between SD and Parkinson's disease (PD). α-synuclein (aSYN) inclusions, the diagnostic hallmark sign of PD, are frequently found in the brain in SD patients and HEX knockout mice, and HEX activity is reduced in the substantia nigra in PD. In this study, we biochemically demonstrate that HEX deficiency in mice causes formation of high-molecular weight (HMW) aSYN and ubiquitin in the brain. As expected from HEX enzymatic function requirements, overexpression in vivo of HEXA and B combined, but not either of the subunits expressed alone, increased HEX activity as evidenced by histochemical assays. Biochemically, such HEX gene expression resulted in increased conversion of GM2 to its breakdown product GM3. In a neurodegenerative model of overexpression of aSYN in rats, increasing HEX activity by AAV6 gene transfer in the substantia nigra reduced aSYN embedding in lipid compartments and rescued dopaminergic neurons from degeneration. Overall, these data are consistent with a paradigm shift where lipid abnormalities are central to or preceding protein changes typically associated with PD.
Identifiants
pubmed: 32762772
doi: 10.1186/s40478-020-01004-6
pii: 10.1186/s40478-020-01004-6
pmc: PMC7409708
doi:
Substances chimiques
Gangliosides
0
Lipids
0
alpha-Synuclein
0
beta-N-Acetylhexosaminidases
EC 3.2.1.52
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
127Subventions
Organisme : NIA NIH HHS
ID : R01AG060195
Pays : United States
Organisme : U.S. Department of Defense
ID : W81XWH2010368
Pays : International
Organisme : NIA NIH HHS
ID : R01 AG060195
Pays : United States
Organisme : Wellcome Trust
ID : 202834/Z/16/Z
Pays : United Kingdom
Organisme : U.S. Department of Defense
ID : W81XWH2010371
Pays : International
Organisme : NINDS NIH HHS
ID : 1R01NS092667
Pays : United States
Références
Cell Struct Funct. 1989 Oct;14(5):561-8
pubmed: 2515920
Biochemistry. 2007 Feb 20;46(7):1868-77
pubmed: 17253773
PLoS One. 2014 Jun 09;9(6):e98906
pubmed: 24911099
Front Neurol. 2019 Oct 09;10:1053
pubmed: 31649605
Mol Neurodegener. 2019 Nov 8;14(1):40
pubmed: 31703585
Lancet Neurol. 2019 Dec;18(12):1091-1102
pubmed: 31701892
J Neurosci. 2004 Jul 28;24(30):6715-23
pubmed: 15282274
Nature. 1975 Nov 20;258(5532):262-4
pubmed: 1202359
Antioxid Redox Signal. 2015 Aug 20;23(6):550-64
pubmed: 26094487
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10373-10378
pubmed: 16801539
Nat Neurosci. 2019 Jul;22(7):1099-1109
pubmed: 31235907
Trends Neurosci. 2007 May;30(5):194-202
pubmed: 17408759
PLoS One. 2018 Jun 14;13(6):e0199189
pubmed: 29902255
J Vis Exp. 2017 Sep 1;(127):
pubmed: 28892024
Annu Rev Biochem. 2019 Jun 20;88:461-485
pubmed: 31220974
J Microsc. 1999 Mar;193(Pt 3):199-211
pubmed: 10348656
J Neurosci. 2013 Jun 19;33(25):10195-208
pubmed: 23785136
N Engl J Med. 2009 Oct 22;361(17):1651-61
pubmed: 19846850
Biochim Biophys Acta Proteins Proteom. 2018 Aug 2;:
pubmed: 30077783
Anal Biochem. 2004 Aug 15;331(2):275-82
pubmed: 15265733
Nat Rev Dis Primers. 2017 Mar 23;3:17013
pubmed: 28332488
Nat Genet. 1995 Oct;11(2):170-6
pubmed: 7550345
Glycoconj J. 2009 Nov;26(8):945-52
pubmed: 18473163
Hum Mol Genet. 2014 Feb 1;23(3):730-48
pubmed: 24057669
Brain. 2013 Jul;136(Pt 7):2130-46
pubmed: 23757764
J Neuroinflammation. 2019 Jul 22;16(1):153
pubmed: 31331333
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9110-5
pubmed: 11481478
J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):148-156
pubmed: 30279211
J Neurosci. 2002 Apr 1;22(7):2780-91
pubmed: 11923443
J Neurochem. 2008 Jun;105(5):1861-72
pubmed: 18248617
Annu Rev Med. 2015;66:471-86
pubmed: 25587658
Cell Death Differ. 2007 Mar;14(3):511-23
pubmed: 16888648
Mol Neurobiol. 2019 Feb;56(2):1344-1355
pubmed: 29948939
NPJ Parkinsons Dis. 2019 Apr 17;5:6
pubmed: 31016231
Nature. 2014 Jun 5;510(7503):68-75
pubmed: 24899306
J Neurochem. 2009 Jan;108(2):465-74
pubmed: 19012742
Exp Neurol. 2008 Jan;209(1):89-100
pubmed: 18028909
Acta Neuropathol. 2007 Nov;114(5):481-9
pubmed: 17653558
Toxicol Pathol. 2010 Dec;38(7):1011-25
pubmed: 21030683
Ann Clin Transl Neurol. 2015 Apr;2(4):433-8
pubmed: 25909088
Brain. 2017 Dec 1;140(12):3191-3203
pubmed: 29140481
Neurochem Res. 2011 Sep;36(9):1706-14
pubmed: 21399908
Sci Rep. 2018 Oct 12;8(1):15207
pubmed: 30315256
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9483-8
pubmed: 19470479
Crit Rev Biochem Mol Biol. 1990;25(6):385-414
pubmed: 2127241
Methods Mol Biol. 2018;1804:1-17
pubmed: 29926402
J Neurosci. 2009 Mar 18;29(11):3365-73
pubmed: 19295143
PLoS One. 2011 Mar 07;6(3):e17698
pubmed: 21408191
J Mol Biol. 2011 May 13;408(4):654-69
pubmed: 21396938
J Neurochem. 1971 Dec;18(12):2469-89
pubmed: 5135907
Exp Neurol. 2016 Oct;284(Pt A):38-49
pubmed: 27453479
Mol Genet Metab. 2004 Jul;82(3):192-207
pubmed: 15234332
Biochem Biophys Res Commun. 2011 Mar 25;406(4):524-8
pubmed: 21333627
Nat Med. 1996 Apr;2(4):424-9
pubmed: 8597952